341 related articles for article (PubMed ID: 23620465)
1. Nystatin nanosizing enhances in vitro and in vivo antifungal activity against Candida albicans.
Melkoumov A; Goupil M; Louhichi F; Raymond M; de Repentigny L; Leclair G
J Antimicrob Chemother; 2013 Sep; 68(9):2099-105. PubMed ID: 23620465
[TBL] [Abstract][Full Text] [Related]
2. An ex-vivo oral mucosa infection model for the evaluation of the topical activity of antifungal agents.
Ohnemus U; Willers C; Bubenheim M; Horstkotte MA; Houdek P; Fischer F; Schmage P; Moll I; Brandner JM
Mycoses; 2008 Jan; 51(1):21-9. PubMed ID: 18076591
[TBL] [Abstract][Full Text] [Related]
3. Use of photodynamic therapy and chitosan for inactivacion of Candida albicans in a murine model.
Fabio CA; Yolanda MB; Carmen GM; Francisco C; Antonio Julián B; Leonor PL; Jesús S
J Oral Pathol Med; 2016 Sep; 45(8):627-33. PubMed ID: 26991463
[TBL] [Abstract][Full Text] [Related]
4. Innovative formulation of nystatin particulate systems in toothpaste for candidiasis treatment.
Pinto Reis C; Vasques Roque L; Baptista M; Rijo P
Pharm Dev Technol; 2016; 21(3):282-7. PubMed ID: 25567611
[TBL] [Abstract][Full Text] [Related]
5. Antifungal activities of two new azasordarins, GW471552 and GW471558, in experimental models of oral and vulvovaginal candidiasis in immunosuppressed rats.
Martinez A; Ferrer S; Santos I; Jimenez E; Sparrowe J; Regadera J; De Las Heras FG; Gargallo-Viola D
Antimicrob Agents Chemother; 2001 Dec; 45(12):3304-9. PubMed ID: 11709301
[TBL] [Abstract][Full Text] [Related]
6. The comparative study of antifungal activity of Syzygium aromaticum, Punica granatum and nystatin on Candida albicans; an in vitro study.
Mansourian A; Boojarpour N; Ashnagar S; Momen Beitollahi J; Shamshiri AR
J Mycol Med; 2014 Dec; 24(4):e163-8. PubMed ID: 25442923
[TBL] [Abstract][Full Text] [Related]
7. Study of anticandidal activity of carvacrol and eugenol in vitro and in vivo.
Chami N; Bennis S; Chami F; Aboussekhra A; Remmal A
Oral Microbiol Immunol; 2005 Apr; 20(2):106-11. PubMed ID: 15720571
[TBL] [Abstract][Full Text] [Related]
8. Activity of an Intralipid formulation of nystatin in murine systemic candidiasis.
Semis R; Mendlovic S; Polacheck I; Segal E
Int J Antimicrob Agents; 2011 Oct; 38(4):336-40. PubMed ID: 21839619
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic efficacy of halocidin-derived peptide HG1 in a mouse model of Candida albicans oral infection.
Shin SH; Lee YS; Shin YP; Kim B; Kim MH; Chang HR; Jang WS; Lee IH
J Antimicrob Chemother; 2013 May; 68(5):1152-60. PubMed ID: 23302580
[TBL] [Abstract][Full Text] [Related]
10. Antifungal activity and mode of action of thymol and its synergism with nystatin against Candida species involved with infections in the oral cavity: an in vitro study.
de Castro RD; de Souza TM; Bezerra LM; Ferreira GL; Costa EM; Cavalcanti AL
BMC Complement Altern Med; 2015 Nov; 15():417. PubMed ID: 26601661
[TBL] [Abstract][Full Text] [Related]
11. Nystatin pastilles and suspension in the treatment of oral candidosis.
Millns B; Martin MV
Br Dent J; 1996 Sep; 181(6):209-11. PubMed ID: 8885454
[TBL] [Abstract][Full Text] [Related]
12. [Sensitivity of Candida strains to polyenic antibiotics in the treatment of oral candidiasis].
Boĭko GI; Sosnin GP; Adarchenko AA; Moroz GS
Antibiotiki; 1984 Nov; 29(11):869-72. PubMed ID: 6395795
[TBL] [Abstract][Full Text] [Related]
13. In vitro fluconazole and nystatin susceptibility and clinical outcome in complicated vulvovaginal candidosis.
Fan SR; Liu XP
Mycoses; 2011 Nov; 54(6):501-5. PubMed ID: 20406393
[TBL] [Abstract][Full Text] [Related]
14. The influence of antifungal drugs on virulence properties of Candida albicans in patients with diabetes mellitus.
Willis AM; Coulter WA; Fulton CR; Hayes JR; Bell PM; Lamey PJ
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Mar; 91(3):317-21. PubMed ID: 11250629
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo activity of Melaleuca alternifolia mixed with tissue conditioner on Candida albicans.
Catalán A; Pacheco JG; Martínez A; Mondaca MA
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Mar; 105(3):327-32. PubMed ID: 18280967
[TBL] [Abstract][Full Text] [Related]
16. Enhancement in antifungal activity of eugenol in immunosuppressed rats through lipid nanocarriers.
Garg A; Singh S
Colloids Surf B Biointerfaces; 2011 Oct; 87(2):280-8. PubMed ID: 21689909
[TBL] [Abstract][Full Text] [Related]
17. In vivo imaging of disseminated murine Candida albicans infection reveals unexpected host sites of fungal persistence during antifungal therapy.
Jacobsen ID; Lüttich A; Kurzai O; Hube B; Brock M
J Antimicrob Chemother; 2014 Oct; 69(10):2785-96. PubMed ID: 24951534
[TBL] [Abstract][Full Text] [Related]
18. [Phenomenon of increased resistance of yeast-like fungi to nystatin].
Nierebińska E; Gwieździński Z; Urbanowski S; Pracz M
Wiad Lek; 1992 Jun; 45(11-12):427-9. PubMed ID: 1441524
[TBL] [Abstract][Full Text] [Related]
19. In vivo and in vitro activity of a bis-arylidenecyclo-alkanone against fluconazole-susceptible and -resistant isolates of Candida albicans.
de Sá NP; de Paula LFJ; Lopes LFF; Cruz LIB; Matos TTS; Lino CI; de Oliveira RB; de Souza-Fagundes EM; Fuchs BB; Mylonakis E; Johann S
J Glob Antimicrob Resist; 2018 Sep; 14():287-293. PubMed ID: 29715565
[TBL] [Abstract][Full Text] [Related]
20. Oral Administration of Human Polyvalent IgG by Mouthwash as an Adjunctive Treatment of Chronic Oral Candidiasis.
Pedraza-Sánchez S; Méndez-León JI; Gonzalez Y; Ventura-Ayala ML; Herrera MT; Lezana-Fernández JL; Bellanti JA; Torres M
Front Immunol; 2018; 9():2956. PubMed ID: 30627128
[No Abstract] [Full Text] [Related]
[Next] [New Search]
